{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:33:42Z","timestamp":1793676822240,"version":"4.5.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23435-8","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T12:14:08Z","timestamp":1764245648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Transfer learning with multiomics integration and deep neural networks reveals drug resistance mechanisms in cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Semih","family":"Alpsoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman Ugur","family":"Sezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"23435_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-1-0716-2553-8_16","volume":"2543","author":"GES Chaudhry","year":"2022","unstructured":"Chaudhry, G. E. S., Akim, A. M., Sung, Y. Y. & Muhammad, T. S. T. Cancer and apoptosis. Methods Mol. Biol. 2543, 191\u2013210 (2022).","journal-title":"Methods Mol. Biol."},{"key":"23435_CR2","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"23435_CR3","doi-asserted-by":"publisher","first-page":"205031212110343","DOI":"10.1177\/20503121211034366","volume":"9","author":"DT Debela","year":"2021","unstructured":"Debela, D. T. et al. New approaches and procedures for cancer treatment: current perspectives. SAGE open. Med. 9, 20503121211034370 (2021).","journal-title":"SAGE open. Med."},{"key":"23435_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/cancers12041009","volume":"12","author":"V Gambardella","year":"2020","unstructured":"Gambardella, V. et al. Personalized medicine: recent progress in cancer therapy. Cancers (Basel). 12, 1009 (2020).","journal-title":"Cancers (Basel)"},{"key":"23435_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15171\/apb.2017.041","volume":"7","author":"B Mansoori","year":"2017","unstructured":"Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S. & Baradaran, B. The different mechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull. 7, 339\u2013348 (2017).","journal-title":"Adv. Pharm. Bull."},{"key":"23435_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan, S. U., Fatima, K., Aisha, S. & Malik, F. Unveiling the mechanisms and challenges of cancer drug resistance. Cell. Commun. Signal. 22, 109 (2024).","journal-title":"Cell. Commun. Signal."},{"key":"23435_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers13040806","volume":"13","author":"N El-Sayes","year":"2021","unstructured":"El-Sayes, N., Vito, A. & Mossman, K. Tumor heterogeneity: A great barrier in the age of cancer immunotherapy. Cancers (Basel). 13, 806 (2021).","journal-title":"Cancers (Basel)"},{"key":"23435_CR8","doi-asserted-by":"crossref","unstructured":"Heppner, G. H., Shapiro, W. R. & Rankin, J. K. Tumor heterogeneity. In Pediatric Oncology 1: with a Special Section on Rare Primitive Neuroectodermal Tumors (eds Humphrey, G. B. et al.) 99\u2013116 https:\/\/doi.org\/10.1007\/978\u221294\u2212009\u22128219\u22122_4 (Springer Netherlands, 1981) .","DOI":"10.1007\/978-94-009-8219-2_4"},{"key":"23435_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"ZF Lim","year":"2019","unstructured":"Lim, Z. F. & Ma, P. C. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol. 12, 134 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"23435_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s42003-019-0572-6","volume":"2","author":"NJ Epsi","year":"2019","unstructured":"Epsi, N. J., Panja, S., Pine, S. R. & Mitrofanova, A. pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma. Commun. Biol. 2, 334 (2019).","journal-title":"Commun. Biol."},{"key":"23435_CR11","doi-asserted-by":"publisher","first-page":"lqab104","DOI":"10.1093\/nargab\/lqab104","volume":"3","author":"Y Park","year":"2021","unstructured":"Park, Y., Hauschild, A. C. & Heider, D. Transfer learning compensates limited data, batch effects and technological heterogeneity in single-cell sequencing. NAR Genomics Bioinforma. 3, lqab104 (2021). .","journal-title":"NAR Genomics Bioinforma"},{"key":"23435_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.14348\/molcells.2021.0042","volume":"44","author":"YJ Heo","year":"2021","unstructured":"Heo, Y. J., Hwa, C., Lee, G. H., Park, J. M. & An, J. Y. Integrative Multi-Omics approaches in cancer research: from biological networks to clinical subtypes. Mol. Cells. 44, 433\u2013443 (2021).","journal-title":"Mol. Cells"},{"key":"23435_CR13","doi-asserted-by":"publisher","first-page":"i501","DOI":"10.1093\/bioinformatics\/btz318","volume":"35","author":"H Sharifi-Noghabi","year":"2019","unstructured":"Sharifi-Noghabi, H., Zolotareva, O., Collins, C. C. & Ester, M. M. O. L. I. Multi-omics late integration with deep neural networks for drug response prediction. Bioinformatics 35, i501\u2013i509 (2019).","journal-title":"Bioinformatics"},{"key":"23435_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.cherd.2024.08.020","volume":"210","author":"B Zhu","year":"2024","unstructured":"Zhu, B., Ren, S., Wang, P. & Si, F. An inductive transfer regression framework for small sample modeling in power plants. Chem. Eng. Res. Des. 210, 112\u2013129 (2024).","journal-title":"Chem. Eng. Res. Des."},{"key":"23435_CR15","doi-asserted-by":"publisher","first-page":"1086097","DOI":"10.3389\/fmed.2023.1086097","volume":"10","author":"A Partin","year":"2023","unstructured":"Partin, A. et al. Deep learning methods for drug response prediction in cancer: predominant and emerging trends. Front. Med. 10, 1086097 (2023).","journal-title":"Front. Med."},{"key":"23435_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3954","volume":"21","author":"H Gao","year":"2015","unstructured":"Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318\u20131325 (2015).","journal-title":"Nat. Med."},{"key":"23435_CR17","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"K Chang","year":"2013","unstructured":"Chang, K. et al. The cancer genome atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"23435_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, 955\u2013961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"23435_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of Pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"23435_CR20","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/bioinformatics\/btw344","volume":"32","author":"Z Ding","year":"2016","unstructured":"Ding, Z., Zu, S. & Gu, J. Evaluating the molecule-based prediction of clinical drug responses in cancer. Bioinformatics 32, 2891\u20132895 (2016).","journal-title":"Bioinformatics"},{"key":"23435_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883 (2012).","journal-title":"Bioinformatics"},{"key":"23435_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur. J. Cancer. 62, 138\u2013145 (2016).","journal-title":"Eur. J. Cancer"},{"key":"23435_CR23","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"23435_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2019.00858","volume":"10","author":"E Ulgen","year":"2019","unstructured":"Ulgen, E., Ozisik, O. & Sezerman, O. U. PathfindR: an R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front. Genet. 10, 1\u201333 (2019).","journal-title":"Front. Genet."},{"key":"23435_CR25","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"23435_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951 (2019).","journal-title":"Protein Sci."},{"key":"23435_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"23435_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-023-01442-3","volume":"8","author":"M You","year":"2023","unstructured":"You, M. et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal. Transduct. Target. Ther. 8, 196 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"23435_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","volume":"286","author":"A Bonni","year":"1999","unstructured":"Bonni, A. et al. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358\u20131362 (1999).","journal-title":"Science"},{"key":"23435_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-020-2399-y","volume":"11","author":"D Verzella","year":"2020","unstructured":"Verzella, D. et al. Life, death, and autophagy in cancer: NF-\u03baB turns up everywhere. Cell. Death Dis. 11, 210 (2020).","journal-title":"Cell. Death Dis."},{"key":"23435_CR31","doi-asserted-by":"publisher","first-page":"102086","DOI":"10.1016\/j.clinre.2023.102086","volume":"47","author":"X Zhang","year":"2023","unstructured":"Zhang, X., Li, C., Wu, Y. & Cui, P. The research progress of Wnt\/\u03b2-catenin signaling pathway in colorectal cancer. Clin. Res. Hepatol. Gastroenterol. 47, 102086 (2023).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"23435_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu, M. et al. The Hippo signalling pathway and its implications in human health and diseases. Signal. Transduct. Target. Ther. 7, 376 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"23435_CR33","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.1111\/acel.13792","volume":"22","author":"EO Karakaslar","year":"2023","unstructured":"Karakaslar, E. O. et al. Transcriptional activation of Jun and Fos members of the AP\u20131 complex is a conserved signature of immune aging that contributes to inflammaging. Aging Cell. 22, e13792 (2023).","journal-title":"Aging Cell."},{"key":"23435_CR34","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/cancers11060750","volume":"11","author":"D Mishra","year":"2019","unstructured":"Mishra, D. & Banerjee, D. Lactate dehydrogenases as metabolic links between tumor and stroma in the tumor microenvironment. Cancers (Basel). 11, 750 (2019).","journal-title":"Cancers (Basel)"},{"key":"23435_CR35","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ccell.2016.08.005","volume":"30","author":"L Brisson","year":"2016","unstructured":"Brisson, L. et al. Lactate dehydrogenase B controls lysosome activity and autophagy in cancer. Cancer Cell. 30, 418\u2013431 (2016).","journal-title":"Cancer Cell."},{"key":"23435_CR36","doi-asserted-by":"publisher","first-page":"e0125976","DOI":"10.1371\/journal.pone.0125976","volume":"10","author":"W Sun","year":"2015","unstructured":"Sun, W. et al. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma. PLoS One. 10, e0125976 (2015).","journal-title":"PLoS One"},{"key":"23435_CR37","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/ijms20092085","volume":"20","author":"K Urba\u0144ska","year":"2019","unstructured":"Urba\u0144ska, K. & Orzechowski, A. Unappreciated role of LDHA and LDHB to control apoptosis and autophagy in tumor cells. Int. J. Mol. Sci. 20, 2085 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"23435_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He, J. et al. Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies. Signal. Transduct. Target. Ther. 9, 209 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"23435_CR39","first-page":"1798","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo, M., Inoue, Y., Liu, G. & Tsao, M. S. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J. Thorac. Oncol. Off Publ Int. Assoc. Study Lung Cancer. 16, 1798\u20131809 (2021).","journal-title":"J. Thorac. Oncol. Off Publ Int. Assoc. Study Lung Cancer"},{"key":"23435_CR40","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1128\/MCB.24.10.4361-4371.2004","volume":"24","author":"E Kurenova","year":"2004","unstructured":"Kurenova, E. et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol. Cell. Biol. 24, 4361\u20134371 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"23435_CR41","doi-asserted-by":"publisher","first-page":"e93921","DOI":"10.7554\/eLife.93921.3","volume":"12","author":"T Kim","year":"2025","unstructured":"Kim, T. et al. Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple-negative breast cancer. eLife 12, e93921 (2025).","journal-title":"eLife"},{"key":"23435_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","volume":"6","author":"L Gan","year":"2018","unstructured":"Gan, L. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. Biomark. Res. 6, 10 (2018).","journal-title":"Biomark. Res."},{"key":"23435_CR43","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.7150\/ijms.59177","volume":"18","author":"CW Chou","year":"2021","unstructured":"Chou, C. W., Huang, Y. M., Chang, Y. J., Huang, C. Y. & Hung, C. S. Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer. Int. J. Med. Sci. 18, 2521\u20132531 (2021).","journal-title":"Int. J. Med. Sci."},{"key":"23435_CR44","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/s41416-024-02875-5","volume":"131","author":"EV Egeland","year":"2024","unstructured":"Egeland, E. V. et al. The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy. Br. J. Cancer. 131, 1656\u20131667 (2024).","journal-title":"Br. J. Cancer"},{"key":"23435_CR45","first-page":"385","volume":"9","author":"J Aseervatham","year":"2020","unstructured":"Aseervatham, J. Cytoskeletal Remodeling in Cancer. Biology (Basel) 9, 385 (2020).","journal-title":"Biology (Basel)"},{"key":"23435_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s12013-023-01186-5","volume":"82","author":"X Qin","year":"2024","unstructured":"Qin, X., Zeng, B., Sooranna, S. R. & Li, M. LAMB3 promotes myofibrogenesis and cytoskeletal reorganization in endometrial stromal cells via the RhoA\/ROCK1\/MYL9 pathway. Cell. Biochem. Biophys. 82, 127\u2013137 (2024).","journal-title":"Cell. Biochem. Biophys."},{"key":"23435_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/annrheumdis-2017-212658","volume":"77","author":"K Li","year":"2018","unstructured":"Li, K. et al. Tyrosine kinase Fyn promotes osteoarthritis by activating the \u03b2-catenin pathway. Ann. Rheum. Dis. 77, 935\u2013943 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"23435_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/leu.2013.184","volume":"28","author":"JA McCubrey","year":"2014","unstructured":"McCubrey, J. A. et al. Multifaceted roles of GSK\u20133 and Wnt\/\u03b2-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia 28, 15\u201333 (2014).","journal-title":"Leukemia"},{"key":"23435_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-023-03930-0","volume":"21","author":"S Peng","year":"2023","unstructured":"Peng, S. & Fu, Y. FYN: emerging biological roles and potential therapeutic targets in cancer. J. Transl Med. 21, 84 (2023).","journal-title":"J. Transl Med."},{"key":"23435_CR50","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood.V97.3.608","volume":"97","author":"RD Chernock","year":"2001","unstructured":"Chernock, R. D., Cherla, R. P. & Ganju, R. K. SHP2 and Cbl participate in alpha-chemokine receptor CXCR4-mediated signaling pathways. Blood 97, 608\u2013615 (2001).","journal-title":"Blood"},{"key":"23435_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3727\/096504015X14343704124430","volume":"22","author":"Q Guo","year":"2014","unstructured":"Guo, Q. et al. CXCL12-CXCR4 axis promotes Proliferation, Migration, Invasion, and metastasis of ovarian cancer. Oncol. Res. 22, 247\u2013258 (2014).","journal-title":"Oncol. Res."},{"key":"23435_CR52","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.18632\/aging.203241","volume":"14","author":"D Zi","year":"2022","unstructured":"Zi, D. et al. CXCR4 knockdown enhances sensitivity of Paclitaxel via the PI3K\/Akt\/mTOR pathway in ovarian carcinoma. Aging (Albany NY). 14, 4673\u20134698 (2022).","journal-title":"Aging (Albany NY)"},{"key":"23435_CR53","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1002\/cam4.3953","volume":"10","author":"T Chevalier","year":"2021","unstructured":"Chevalier, T. et al. Cetuximab combined with Paclitaxel or Paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME. Cancer Med. 10, 3952\u20133963 (2021).","journal-title":"Cancer Med."},{"key":"23435_CR54","doi-asserted-by":"publisher","first-page":"103476","DOI":"10.1016\/j.esmoop.2024.103476","volume":"9","author":"T Koyama","year":"2024","unstructured":"Koyama, T. et al. A phase II trial of Paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD\u20131 antibody. ESMO Open. 9, 103476 (2024).","journal-title":"ESMO Open."},{"key":"23435_CR55","doi-asserted-by":"publisher","first-page":"23631","DOI":"10.18632\/oncotarget.4604","volume":"6","author":"ME Irwin","year":"2015","unstructured":"Irwin, M. E., Johnson, B. P., Manshouri, R., Amin, H. M. & Chandra, J. A NOX2\/Egr\u20131\/Fyn pathway delineates new targets for TKI-resistant malignancies. Oncotarget 6, 23631\u201323646 (2015).","journal-title":"Oncotarget"},{"key":"23435_CR56","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.18632\/oncotarget.14012","volume":"8","author":"B Zhao","year":"2017","unstructured":"Zhao, B. et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget 8, 3980\u20134000 (2017).","journal-title":"Oncotarget"},{"key":"23435_CR57","doi-asserted-by":"publisher","first-page":"8473","DOI":"10.1038\/srep08473","volume":"5","author":"J Tan","year":"2015","unstructured":"Tan, J. et al. Genetic variants in the inositol phosphate metabolism pathway and risk of different types of cancer. Sci. Rep. 5, 8473 (2015).","journal-title":"Sci. Rep."},{"key":"23435_CR58","doi-asserted-by":"publisher","first-page":"e23165","DOI":"10.1016\/j.heliyon.2023.e23165","volume":"10","author":"X Di","year":"2024","unstructured":"Di, X. et al. Therapeutic potential of anti-PIK3CG treatment for multiple myeloma via inhibiting c-Myc pathway. Heliyon 10, e23165 (2024).","journal-title":"Heliyon"},{"key":"23435_CR59","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1038\/s41598-020-60707-x","volume":"10","author":"AR Jung","year":"2020","unstructured":"Jung, A. R., Jung, C. H., Noh, J. K., Lee, Y. C. & Eun, Y. G. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma. Sci. Rep. 10, 3652 (2020).","journal-title":"Sci. Rep."},{"key":"23435_CR60","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nm.2646","volume":"18","author":"A Bardelli","year":"2012","unstructured":"Bardelli, A. & J\u00e4nne, P. A. The road to resistance: EGFR mutation and cetuximab. Nat. Med. 18, 199\u2013200 (2012).","journal-title":"Nat. Med."},{"key":"23435_CR61","doi-asserted-by":"publisher","first-page":"E3855","DOI":"10.1073\/pnas.1510733112","volume":"112","author":"J Phuchareon","year":"2015","unstructured":"Phuchareon, J., McCormick, F., Eisele, D. W. & Tetsu, O. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets\u22121 function. Proc. Natl. Acad. Sci. 112, E3855-63 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"23435_CR62","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/cancers11071037","volume":"11","author":"V Atsaves","year":"2019","unstructured":"Atsaves, V., Leventaki, V., Rassidakis, G. Z. & Claret, F. X. AP\u20131 transcription factors as regulators of immune responses in cancer. Cancers (Basel). 11, 1037 (2019).","journal-title":"Cancers (Basel)"},{"key":"23435_CR63","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios, E. H. & Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990\u20138000 (2004).","journal-title":"Oncogene"},{"key":"23435_CR64","doi-asserted-by":"publisher","first-page":"865819","DOI":"10.1155\/2011\/865819","volume":"2011","author":"B Sen","year":"2011","unstructured":"Sen, B. & Johnson, F. M. Regulation of SRC family kinases in human cancers. J. Signal Transduct. 2011, 865819 (2011).","journal-title":"J. Signal Transduct."},{"key":"23435_CR65","doi-asserted-by":"publisher","first-page":"109940","DOI":"10.1016\/j.biopha.2020.109940","volume":"125","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. ALDH1A1 maintains the cancer stem-like cells properties of esophageal squamous cell carcinoma by activating the AKT signal pathway and interacting with \u03b2-catenin. Biomed. Pharmacother. 125, 109940 (2020).","journal-title":"Biomed. Pharmacother"},{"key":"23435_CR66","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-020-07153-0","volume":"20","author":"C Gan","year":"2020","unstructured":"Gan, C. et al. The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma. BMC Cancer. 20, 672 (2020).","journal-title":"BMC Cancer"},{"key":"23435_CR67","doi-asserted-by":"publisher","first-page":"30489","DOI":"10.1038\/srep30489","volume":"6","author":"T Kawai","year":"2016","unstructured":"Kawai, T. et al. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci. Rep. 6, 30489 (2016).","journal-title":"Sci. Rep."},{"key":"23435_CR68","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41416-020-0758-1","volume":"122","author":"Y Morimoto","year":"2020","unstructured":"Morimoto, Y. et al. miR\u20134711\u20135p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells. Br. J. Cancer. 122, 1037\u20131049 (2020).","journal-title":"Br. J. Cancer"},{"key":"23435_CR69","doi-asserted-by":"publisher","first-page":"1434378","DOI":"10.3389\/fcell.2024.1434378","volume":"12","author":"S Gou","year":"2024","unstructured":"Gou, S., Wu, A. & Luo, Z. Integrins in cancer stem cells. Front. cell. Dev. Biol. 12, 1434378 (2024).","journal-title":"Front. cell. Dev. Biol."},{"key":"23435_CR70","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi, L. T. H. et al. Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells Int. 2018, 5416923 (2018).","journal-title":"Stem Cells Int."},{"key":"23435_CR71","doi-asserted-by":"publisher","first-page":"165339","DOI":"10.1016\/j.bbadis.2018.11.015","volume":"1866","author":"MR Makena","year":"2020","unstructured":"Makena, M. R., Ranjan, A., Thirumala, V. & Reddy, A. P. Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance. Biochim. Biophys. Acta - Mol. Basis Dis. 1866, 165339 (2020).","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"23435_CR72","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.21037\/tcr-24-933","volume":"13","author":"H Liu","year":"2024","unstructured":"Liu, H., Huang, Y., Zhao, C., Wang, G. & Wang, X. ABALON regulates mitophagy and 5-FU sensitivity in colorectal cancer via PINK1-Parkin pathway. Transl Cancer Res. 13, 6201\u20136218 (2024).","journal-title":"Transl Cancer Res."},{"key":"23435_CR73","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1245\/s10434-017-6096-8","volume":"24","author":"K Yamashita","year":"2017","unstructured":"Yamashita, K. et al. High expression of the Mitophagy-Related protein Pink1 is associated with a poor response to chemotherapy and a poor prognosis for patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann. Surg. Oncol. 24, 4025\u20134032 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"23435_CR74","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1124\/mol.114.092544","volume":"86","author":"L Qin","year":"2014","unstructured":"Qin, L., Dong, Z. & Zhang, J. T. Reversible epigenetic regulation of 14-3-3\u03c3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol. Pharmacol. 86, 561\u2013569 (2014).","journal-title":"Mol. Pharmacol."},{"key":"23435_CR75","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4143\/crt.2022.1600","volume":"56","author":"P Cao","year":"2024","unstructured":"Cao, P. et al. Gemcitabine inhibits the progression of pancreatic cancer by restraining the WTAP\/MYC chain in an m6A-Dependent manner. Cancer Res. Treat. 56, 259\u2013271 (2024).","journal-title":"Cancer Res. Treat."},{"key":"23435_CR76","doi-asserted-by":"publisher","first-page":"13155","DOI":"10.3390\/ijms241713155","volume":"24","author":"D Stukas","year":"2023","unstructured":"Stukas, D. et al. Targeting AHR increases pancreatic cancer cell sensitivity to gemcitabine through the ELAVL1-DCK pathway. Int. J. Mol. Sci. 24, 13155 (2023). .","journal-title":"Int. J. Mol. Sci."},{"key":"23435_CR77","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/sim.9406","volume":"41","author":"EW van Zwet","year":"2022","unstructured":"van Zwet, E. W. & Goodman, S. N. How large should the next study be? Predictive power and sample size requirements for replication studies. Stat. Med. 41, 3090\u20133101 (2022).","journal-title":"Stat. Med."},{"key":"23435_CR78","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12864-022-08337-7","volume":"23","author":"PY Wu","year":"2022","unstructured":"Wu, P. Y. et al. Improvement of prediction ability by integrating multi-omic datasets in barley. BMC Genom. 23, 200 (2022).","journal-title":"BMC Genom."},{"key":"23435_CR79","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12911-024-02642-9","volume":"24","author":"Y Li","year":"2024","unstructured":"Li, Y., Herold, T., Mansmann, U. & Hornung, R. Does combining numerous data types in multi-omics data improve or hinder performance in survival prediction? Insights from a large-scale benchmark study. BMC Med. Inf. Decis. Mak. 24, 244 (2024).","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"23435_CR80","doi-asserted-by":"publisher","first-page":"btaf002","DOI":"10.1093\/bioinformatics\/btaf002","volume":"41","author":"X Ouyang","year":"2024","unstructured":"Ouyang, X. et al. Improving generalizability of drug-target binding prediction by pre-trained multi-view molecular representations. Bioinformatics 41, btaf002 (2024).","journal-title":"Bioinformatics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23435-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23435-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T14:04:22Z","timestamp":1764252262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23435-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23435"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23435-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42295"}}